[144] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. – Form 144 filing

An unnamed insider intends to sell 1,761 common shares of Agios Pharmaceuticals, Inc. (AGIO) through Morgan Stanley Smith Barney on 24 June 2025. The shares, worth about $60,596, were obtained the same day via the vesting of restricted stock units. With 57.9 million shares outstanding, the proposed sale equates to roughly 0.003 % of total shares, indicating an immaterial ownership change. No other insider sales were reported in the past three months, and the filer certified that no undisclosed adverse information is known.

Insights

Securities Analyst

TL;DR: Routine Form 144 for 1,761 AGIO shares; negligible dilution or signaling impact.

The filing discloses a prospective disposition equaling 0.003 % of shares outstanding—far below thresholds that typically influence liquidity or insider-sentiment models. Because the shares stem from RSU vesting on the same day, the trade appears to be a standard liquidity event rather than an expression of long-term view. No pattern of recent sales is indicated, and the filing contains no operational or financial metrics. Consequently, valuation and forecast models for AGIO remain unchanged.

Corporate Governance Expert

TL;DR: Standard compliance notice; no governance red flags detected.

The unidentified filer met Rule 144 disclosure requirements, including broker name, sale amount, and attestation of no material non-public information. Absence of the relationship-to-issuer field makes it impossible to gauge seniority, yet the small dollar value and one-time RSU vesting suggest a low-level employee or routine executive diversification. Governance risk remains minimal given the de minimis stake and transparent timing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1761	60596.00	57915199	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/24/2025	Vesting of Restricted Stock Units	Issuer			1761	06/24/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Agios (AGIO) shares are being sold under this Form 144?

1,761 common shares are proposed for sale.

What is the approximate market value of the AGIO shares to be sold?

The aggregate value stated is $60,596.

When is the planned sale date for the AGIO shares?

The filer listed 24 June 2025 as the approximate sale date.

What percentage of Agios’ outstanding shares does this sale represent?

Approximately 0.003 % of the 57.9 million shares outstanding.

Were there any other insider sales of AGIO shares in the past three months?

No. The filing states “Nothing to Report” for prior 3-month sales.